Keryx Biopharmaceuticals, Inc. (KERX) Price Down, Not Company’s Potential
Biotech investors are patient people. They are also diligent in their research; looking closely into a company’s compounds and the market potential that surrounds them. Keryx Biopharmaceuticals, Inc. is a company that has been the focus of several articles recently due to the dip in share price which is offering an opportunity for value pricing of a company that is pushing forward with late-stage research on its novel compounds. Regarding therapies for end-stage renal disease (ESRD), a more than billion-dollar market controlled by Genzyme (NASDAQ:GENZ) with Renagel and Renvela, there still remains a void that can be filled by a…